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1 I. 
Prolonged Survival After Liver Transplantation and Cancer 
Chemotherapy for Advanced-Stage Hepatocellular Carcinoma 
6.1. Carr, R. Selby, J. Madariaga, S. Iwatsuki, and T.E. Starzl 
L IVER transplantation for advanced-stage hepatocellu-lar carcinoma (HCC) has been associated with high 
tumor recurrence rates. and poor long-term survival. 1•2 
Cancer chemotherapy for HCC using standard drugs ad-
ministered intravenously has also been associated with 
poor survival and negligible response rates.3 However, 
several recent reports have indicated reproducible re-
sponse rates involving greater than 50% of patients when 
various anticancer agents have been administered via the 
hepatic artery for the treatment of HCC.4•5 We therefore 
investigated the feasibility of combining both treatment 
modalities, to determine whether chemotherapy-induced 
tumor cell destruction prior to surgical manipulation might 
decrease post-orthotopic liver transplantation (post-
OLTx) tumor recurrences and thus enhance survival. 
MATERIALS AND METHODS 
Patients with advanced stages III and IVa HCC who were 
considered for OLTx because of extensive unresectable tumor or 
tumor that was unresectable due to underlying cirrhosis were 
offered pretransplant intrahepatic arterial chemotherapy if their 
bilirubin was less than 2.S mg/dL. their platelets were greater than 
50,000 per milliliter, and there was no uncorrectable coagulopa-
thy. Not all patients accepted this treatment and many patients 
with Child's class C cirrhosis could not be considered for it. 
Chemotherapy was given into the right or left hepatic artery using 
60 mg/m2 doxorubicin and 100 mg/m2 cisplatin in 100 mL of 
normal saline administered by slow infusion over 30 minutes. 
They also received 3 million units of a-interferon subcutaneously, 
three times per week continuously. Treatments were repeated 
every 4 weeks. blood counts permitting, for a minimum of three 
cycles. Thereafter. patients were placed on the liver transplant 
candidate list to await a donor liver and received continued 
monthly cycles of chemotherapy until the time of transplantation. 
All patients received FK 506 as immunosuppressant whether or 
not they received chemotherapy. Patients receiving chemother-
apy and a transplant continued with the same chemotherapy with 
drugs, but administered intravenously for a nominal 12 monthly 
cycles after transplantation. 
RESULTS 
Eleven patients were treated with preoperative chemo-
therapy and had a minimum of 12 months' posttransplant 
follow-up or have died (Table l). One patient had recur-
rence at 7 months and subsequently died within I year. 
There were no other new recurrences and no other deaths 
in this group within the first year (91% I-year surviVal, 82% 
disease-free). A second patient had a recurrence at 14 
months and died at 15 months posttransplant. A third 
patient had unrecognized lung metastases at the time of 
transplant and continues with slowly progressive disease 
Table 1. Resulta of Uver TraMPlantation for 
HepMoceIlular carcinoma 
Post-oLTx 
Recunence SuMval 
Pa1Ient (Months) (Months) 
Chemotherapy 
1 0 25' 
2 8 25' 
3 0 21" 
4 0 21' 
5 0 17' 
6 _t 16' 
7 14 15 
a 0 13" 
9 0 13' 
10 7 8 
11 0 12' 
No chemotherapy 
1 5 17 
2 8 
3 6 12 
4 2 6 
5 6 9 
6 0 16' 
7 5 11 
8 2 5 
9 5 9 
10 20 24 
11 0 17' 
12 14 25' 
13 5 6 
14 23 33' 
'Ongoing llUlVlvai. 
tUrncogrized lung ~ at the time of OLTx. 
HCC 
Stage 
III 
IVa 
IVa 
III 
III 
IVb 
IVa 
IVa 
III 
IVa 
III 
IVa 
IVa 
IVa 
IVa 
IVa 
III 
IVa 
III 
IVa 
III 
III 
III 
IVa 
IVa 
at 16 months' post-OLTx follow-up. The second group of 
14 patients had either no chemotherapy or could not 
tolerate the first cycle of chemotherapy so cancer chemo-
therapy was thus subsequently abandoned. Nine patients 
in this group had recurrence within I year and 8 patients 
died within I year of transplant (43% I-year survival, 36% 
disease-free). During this study period an additional 20 
patients were seen with similar advanced-stage nonmeta-
static HCC who had Child's class C cirrhosis and could not 
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receive chemotherapy because of their advanced underly-
ing liver disease. None of these patients survived long 
enough for liver transplantation; the median survival was 3 
months (Fig 1). 
DISCUSSION 
This pilot study shows that it is feasible to give a subset of 
patients with advanced-stage HCC intraarterial chemo-
therapy prior to liver transplantation. This set of patients 
includes those without cirrhosis or with Child's class A 
cirrhosis. Patients with Child's class B cirrhosis were 
heterogeneous with regard to their ability to tolerate the 
chemotherapy. No patients with Child's class C cirrhosis 
fitted our inclusion criteria for the safe administration of 
chemotherapy. Although the numbers are small and the 
30 36 Fig 1. Post-OL Tx survival rates for patients with hepatocellular 
carcinoma. 
follow-up is limited, there appears to be a significant 
difference in the survival rates at 1 year between patients 
receiving a liver transplant with cancer chemotherapy and 
those receiving a liver transplant without chemotherapy. 
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